{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:15Z","timestamp":1740144075379,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Angelini SpA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40261-020-00944-0","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T13:12:01Z","timestamp":1594300321000},"page":"861-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6831-3044","authenticated-orcid":false,"given":"Umberto","family":"Restelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Garc\u00eda-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Lew-Starowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Mierzejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Silvola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Mayoral-van Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"6","key":"944_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195\u2013203.","journal-title":"Schizophr Bull"},{"key":"944_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eurpsy.2017.10.008","volume":"48","author":"G Kov\u00e1cs","year":"2018","unstructured":"Kov\u00e1cs G, Alm\u00e1si T, Millier A, Toumi M, Horv\u00e1th M, K\u00f3czi\u00e1n K, et al. Direct healthcare cost of schizophrenia: European overview. Eur Psychiatry. 2018;48:79\u201392. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.10.008.","journal-title":"Eur Psychiatry"},{"issue":"9657","key":"944_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet"},{"issue":"4","key":"944_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/ijnp\/pyaa004","volume":"23","author":"M G\u00f3mez-Revuelta","year":"2020","unstructured":"G\u00f3mez-Revuelta M, Pelayo-Ter\u00e1n JM, Juncal-Ruiz M, V\u00e1zquez-Bourgon J, Su\u00e1rez-Pinilla P, Romero-Jim\u00e9nez R, et al. Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine and ziprasidone. Int J Neuropsychopharmacol. 2020;23(4):217\u201329.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"944_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3111\/13696998.2013.809353","volume":"16","author":"K Rajagopalan","year":"2013","unstructured":"Rajagopalan K, O\u2019Day K, Meyer K, Pikalov A, Loebel A. Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release. J Med Econ. 2013;16(8):987\u201396.","journal-title":"J Med Econ"},{"issue":"5","key":"944_CR6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/eip.12752","volume":"13","author":"J Mayoral-van Son","year":"2019","unstructured":"Mayoral-van Son J, Juncal-Ruiz M, Ortiz-Garc\u00eda de la Foz V, Cantarero-Prieto D, Bl\u00e1zquez-Fern\u00e1ndez C, Paz-Zulueta M, et al. Understanding the direct and indirect costs of a first episode of psychosis program: Insights from PAFIP of Cantabria, Spain, during the first year of intervention. Early Interv Psychiatry. 2019;13(5):1182\u201390.","journal-title":"Early Interv Psychiatry."},{"issue":"1","key":"944_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00148365-200806010-00004","volume":"6","author":"JM Olivares","year":"2008","unstructured":"Olivares JM, Rodriguez-Martinez A, Bur\u00f3n JA, Alonso-Escolano D, Rodriguez-Morales A, e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41\u201353.","journal-title":"Appl Health Econ Health Policy."},{"key":"944_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-0447.2006.00917.x","volume":"432","author":"P Guti\u00e9rrez-Recacha","year":"2006","unstructured":"Guti\u00e9rrez-Recacha P, Chisholm D, Haro JM, Salvador-Carulla L, Ayuso-Mateos JL. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. Acta Psychiatr Scand Suppl. 2006;432:29\u201338.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"8","key":"944_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","volume":"46","author":"O Caseiro","year":"2012","unstructured":"Caseiro O, P\u00e9rez-Iglesias R, Mata I, Mart\u00ednez-Garcia O, Pelayo-Ter\u00e1n JM, Tabares-Seisdedos R, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099\u2013105.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"944_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378.","journal-title":"World J Biol Psychiatry."},{"issue":"1","key":"944_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","volume":"147","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month double-blind noninferiority study. Schizophr Res. 2013;147(1):95\u2013102.","journal-title":"Schizophr Res."},{"key":"944_CR12","unstructured":"European Medicines Agency. Latuda: lurasidone. 2014. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/latuda. Accessed 23 June 2020."},{"issue":"5","key":"944_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","volume":"56","author":"WM Greenberg","year":"2017","unstructured":"Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017;56(5):493\u2013503.","journal-title":"Clin Pharmacokinet"},{"key":"944_CR14","unstructured":"European Medicines Agency. Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine). 2010. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/questions-answers-seroquel-xr-associated-names-50-150-200-300-400-mg-prolonged-release-tablets_en.pdf. Accessed 23 June 2020."},{"key":"944_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"944_CR16","unstructured":"Italian Ministry of Health. Rapporto salute mentale. Analisi dei dati del Sistema Informativo per la Salute Mentale (SISM) Anno 2017. December 2018. http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2841_allegato.pdf. Accessed 25 June 2020."},{"key":"944_CR17","unstructured":"Eurostat. Population on 1 January. 2019. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/tps00001\/default\/table?lang=en. Accessed 23 June 2020."},{"key":"944_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF03320858","volume":"6","author":"C Rubio-Terr\u00e9s","year":"2009","unstructured":"Rubio-Terr\u00e9s C, Montejo Gonz\u00e1lez AL, Puchol Incertis M, \u00c1lvarez SC. An\u00e1lisis farmacoecon\u00f3mico del cambio de tratamiento antipsic\u00f3tico, por ineficacia o efectos adversos, a quetiapina de liberaci\u00f3n prolongada. Pharmacoecon Span Res Artic. 2009;6:105\u201314. https:\/\/doi.org\/10.1007\/BF03320858.","journal-title":"Pharmacoecon Span Res Artic"},{"issue":"10","key":"944_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"944_CR20","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med."},{"issue":"14","key":"944_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12888-014-0298-4","volume":"2","author":"T Dilla","year":"2014","unstructured":"Dilla T, M\u00f6ller J, O'Donohoe P, \u00c1lvarez M, Sacrist\u00e1n JA, Happich M, Tockhorn A. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain: a cost-effectiveness comparison. BMC Psychiatry. 2014;2(14):298.","journal-title":"BMC Psychiatry"},{"issue":"7","key":"944_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00127-004-0776-y","volume":"39","author":"S Peir\u00f2","year":"2004","unstructured":"Peir\u00f2 S, G\u00f3mez G, Navarro M, Guadarrama I, Rejas J, Psychosp Group. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Soc Psychiatry Psychiatr Epidemiol. 2004;39(7):507\u201313.","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"issue":"2","key":"944_CR23","first-page":"95","volume":"9","author":"P Berto","year":"2008","unstructured":"Berto P, Negrini C, Ferrannini L. Analisi costo-efficacia di paliperidone ER nel trattamento delle ricadute della schizofrenia, nella prospettiva del Sistema Sanitario Nazionale italiano. Farmacoeconomia e Percorsi Clinici. 2008;9(2):95\u2013108.","journal-title":"Farmacoeconomia e Percorsi Clinici"},{"key":"944_CR24","unstructured":"International Monetary Fund. Inflation average consumer prices: Italy and Spain. 2019. https:\/\/www.imf.org\/external\/datamapper\/PCPIPCH@WEO\/OEMDC\/ITA\/ESP. Accessed 23 June 2020."},{"issue":"2","key":"944_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/schbul\/sbu001","volume":"40","author":"S Leucht","year":"2014","unstructured":"Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40(2):314\u201326.","journal-title":"Schizophr Bull"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-020-00944-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00944-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:23:25Z","timestamp":1625786605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-020-00944-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00944-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"9 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This analysis was funded by an unconditional grant from Angelini SpA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Umberto Restelli, Davide Croce, and Sofia Silvola declare grants received by one of their institutions to conduct the analysis. Manuel Garc\u00eda-Go\u00f1i participated through his university in a research project financed by Angelini whose result is the manuscript. Benedicto Crespo-Facorro declares advisory board honoraria from Lundbeck, Otsuka, Cassen Recordati, Teva Neuroscience, and Angelini; and speaker\u2019s honoraria from Lundbeck, Otsuka, and Janssen Cilag. Michal Lew-Starowicz declares advisory board honoraria from Novo Nordisk; travel\/meeting expenses and manuscript preparation and reviewing supported by CREMS Srl, and receiving honoraria for lectures from Abbvie, Angelini, Autrovitas Apotex, CROS-CRO, MCO International Srl, Mylan Healthcare, Lundbeck, Sanofi, and Servier. Pawel Mierzejewski, Jacqueline Mayoral-van Son, and Paola Rocca have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data used in the analysis are already available in the literature and data sources are reported in the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}